SCHEMBL4365770

SCHEMBL4365770

O=C(Cl)N1CCC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25405952 0.80 DPP4 (0.37)
SCHEMBL28869374 0.76
SCHEMBL13324943 0.69 ITGB1 (0.32)
SCHEMBL14738699 0.67
SCHEMBL29133800 0.57
Hydrochloric Acid SCHEMBL27666401 0.55
SCHEMBL25395345 0.55
SCHEMBL26287179 0.55
SCHEMBL9737159 0.55 ALDH1A1 (0.40)
SCHEMBL8053410 0.54

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025040089-A1 NOVEL HETEROCYCLIC COMPOUND FOR SELECTIVELY REGULATING CANNABINOID CB1 FUNCTION 德睿智药(苏州)新药研发有限公司 2025-02-27 WO disclosed
US-8236821-B2 Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity JENRIN DISCOVERY, INC. (US) 2012-08-07 US disclosed
US-20090286758-A1 SUBSTITUTED N-PHENYL-5-PHENYL-PYRAZOLIN-3-YL AMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2009-11-19 US disclosed